KR100983450B1 - 식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현 - Google Patents

식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현 Download PDF

Info

Publication number
KR100983450B1
KR100983450B1 KR1020077027182A KR20077027182A KR100983450B1 KR 100983450 B1 KR100983450 B1 KR 100983450B1 KR 1020077027182 A KR1020077027182 A KR 1020077027182A KR 20077027182 A KR20077027182 A KR 20077027182A KR 100983450 B1 KR100983450 B1 KR 100983450B1
Authority
KR
South Korea
Prior art keywords
whole blood
mrna
vitamin
blood
exposed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077027182A
Other languages
English (en)
Korean (ko)
Other versions
KR20080019590A (ko
Inventor
마사토 미츠하시
Original Assignee
히다치 가세고교 가부시끼가이샤
히타치케미컬 리서치센터 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히다치 가세고교 가부시끼가이샤, 히타치케미컬 리서치센터 인코포레이티드 filed Critical 히다치 가세고교 가부시끼가이샤
Publication of KR20080019590A publication Critical patent/KR20080019590A/ko
Application granted granted Critical
Publication of KR100983450B1 publication Critical patent/KR100983450B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/071—Agaricus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/746—Morinda
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
KR1020077027182A 2005-04-28 2006-04-28 식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현 Expired - Fee Related KR100983450B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67558005P 2005-04-28 2005-04-28
US60/675,580 2005-04-28

Publications (2)

Publication Number Publication Date
KR20080019590A KR20080019590A (ko) 2008-03-04
KR100983450B1 true KR100983450B1 (ko) 2010-09-20

Family

ID=37215096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077027182A Expired - Fee Related KR100983450B1 (ko) 2005-04-28 2006-04-28 식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현

Country Status (7)

Country Link
US (1) US20080206761A1 (https=)
EP (1) EP1888089B9 (https=)
JP (1) JP4945554B2 (https=)
KR (1) KR100983450B1 (https=)
CN (1) CN101166537B (https=)
AT (1) ATE512234T1 (https=)
WO (1) WO2006116721A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101426930A (zh) * 2004-05-25 2009-05-06 日立化成工业株式会社 检测癌症易感性的方法
JP4772055B2 (ja) * 2004-10-20 2011-09-14 日立化成工業株式会社 ｍＲＮＡの定量により薬剤の投与を選定する方法
JP4800384B2 (ja) * 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
ATE518011T1 (de) 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
JP2009536021A (ja) * 2006-04-07 2009-10-08 日立化成工業株式会社 関節リウマチの患者の末梢血白血球におけるＦＣ受容体媒介性腫瘍壊死因子スーパーファミリ及びケモカインのｍＲＮＡ発現の増大
CN101437549A (zh) * 2006-05-08 2009-05-20 日立化成工业株式会社 通过对薄切肿瘤组织中mRNA表达进行定量测试实体瘤中药物敏感性的方法
EP2209919A4 (en) * 2007-11-14 2011-04-13 Hitachi Chemical Co Ltd ENHANCED EXPRESSION OF FC RECEPTOR TUMOR NECROSIS NECROSIS FACTOR SUPERFAMILY IN THE PERIFERIC BLOOD LEUKOCYTES
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
US9150920B2 (en) 2010-05-07 2015-10-06 Hitachi Chemical Co., Ltd. Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20140147470A1 (en) * 2011-07-18 2014-05-29 Hitachi Chemical C., Ltd. METHODS OF PREDICTING HOST RESPONSIVENESS TO CANCER IMMUNOTHERAPIES BY EX VIVO INDUCTION OF LEUKOCYTE-FUNCTION-ASSOCIATED mRNAs
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925572A (en) * 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) * 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
EP0341904B1 (en) * 1988-05-09 1995-03-29 Temple University of the Commonwealth System of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5474909A (en) * 1992-08-07 1995-12-12 Anticancer, Inc. Noncolorimetric histoculture method for predicting drug response of tumors
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5491063A (en) * 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
ATE471150T1 (de) * 1996-03-26 2010-07-15 Kopreski Michael S Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US5683698A (en) * 1996-08-02 1997-11-04 New England Deaconess Hospital Formulation for alleviating symptoms associated with arthritis
US7514232B2 (en) * 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
CA2377414A1 (en) * 1999-06-15 2000-12-21 John D. Potter Nutrient formulations for disease reduction, and related treatment and component screening methods
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US20020048566A1 (en) * 2000-09-14 2002-04-25 El-Deiry Wafik S. Modulation of cellular apoptosis and methods for treating cancer
ATE480618T1 (de) * 2000-10-31 2010-09-15 Hitachi Chemical Res Ct Inc Methode für das sammeln und das verwenden von kern-mrna
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
WO2003044215A2 (en) * 2001-11-20 2003-05-30 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
FI20020078A7 (fi) * 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6878518B2 (en) * 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
CN1650027B (zh) * 2002-04-24 2010-04-21 日立化成研究中心公司 用于全血mRNA的高通量定量的装置和方法
US7745180B2 (en) * 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
US20040072268A1 (en) * 2002-08-05 2004-04-15 Ramin Shiekhattar Methods for regulating BRCA1-BRCA2-containing complex activity
GB0219642D0 (en) * 2002-08-23 2002-10-02 Gauthier Pierre Method and device for preparing tissues sections
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
CN101426930A (zh) * 2004-05-25 2009-05-06 日立化成工业株式会社 检测癌症易感性的方法
JP4800384B2 (ja) * 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
AU2006294477A1 (en) * 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
ATE518011T1 (de) * 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
JP2009536021A (ja) * 2006-04-07 2009-10-08 日立化成工業株式会社 関節リウマチの患者の末梢血白血球におけるＦＣ受容体媒介性腫瘍壊死因子スーパーファミリ及びケモカインのｍＲＮＡ発現の増大
CN101437549A (zh) * 2006-05-08 2009-05-20 日立化成工业株式会社 通过对薄切肿瘤组织中mRNA表达进行定量测试实体瘤中药物敏感性的方法
EP2209919A4 (en) * 2007-11-14 2011-04-13 Hitachi Chemical Co Ltd ENHANCED EXPRESSION OF FC RECEPTOR TUMOR NECROSIS NECROSIS FACTOR SUPERFAMILY IN THE PERIFERIC BLOOD LEUKOCYTES
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006613A1 (en) 1998-01-20 2002-01-17 Shyjan Andrew W. Methods and compositions for the identification and assessment of cancer therapies

Also Published As

Publication number Publication date
JP4945554B2 (ja) 2012-06-06
EP1888089B9 (en) 2012-08-08
CN101166537A (zh) 2008-04-23
CN101166537B (zh) 2013-01-23
WO2006116721A1 (en) 2006-11-02
KR20080019590A (ko) 2008-03-04
US20080206761A1 (en) 2008-08-28
EP1888089A4 (en) 2009-01-07
JP2008538930A (ja) 2008-11-13
ATE512234T1 (de) 2011-06-15
EP1888089A1 (en) 2008-02-20
EP1888089B1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
KR100983450B1 (ko) 식품보충제에 대한 개별적 다양성 평가의 모델로서 전혈내의 생체 외 유전자 발현
Hall et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production
Piwowarski et al. Urolithins, gut microbiota‐derived metabolites of ellagitannins, inhibit LPS‐induced inflammation in RAW 264.7 murine macrophages
Zhang et al. Effects of anthocyanins from purple sweet potato (Ipomoea batatas L. cultivar Eshu No. 8) on the serum uric acid level and xanthine oxidase activity in hyperuricemic mice
Yu et al. Environmental enteric dysfunction includes a broad spectrum of inflammatory responses and epithelial repair processes
Lee et al. Chloroform extract of aged black garlic attenuates TNF‐α‐induced ROS generation, VCAM‐1 expression, NF‐κB activation and adhesiveness for monocytes in human umbilical vein endothelial cells
Kang et al. [Retracted] The Studies of Chlorogenic Acid Antitumor Mechanism by Gene Chip Detection: The Immune Pathway Gene Expression
Leffa et al. Corrective effects of acerola (Malpighia emarginata DC.) juice intake on biochemical and genotoxical parameters in mice fed on a high-fat diet
US11026917B2 (en) Antioxidative stress compositions, methods of preparing and uses thereof
Barros et al. Triclosan inhibition of acute and chronic inflammatory gene pathways
US20110159500A1 (en) Compositions including ginger for the amelioration or prevention of inflammatory conditions
Reis et al. Brazil nut intake increases circulating miR-454-3p and miR-584-5p in obese women
Castro et al. Resveratrol modulates innate and inflammatory responses in fish leucocytes
JP2008503206A (ja) 癌感受性を測定する方法
Ma et al. Folic acid supplementation repressed hypoxia-induced inflammatory response via ROS and JAK2/STAT3 pathway in human promyelomonocytic cells
Hsieh et al. The novel pterostilbene derivative ANK-199 induces autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg‑related proteins in cisplatin‑resistant CAR human oral cancer cells
KR102699674B1 (ko) 신경퇴행성질환 진단용 신규 바이오 마커 gcn5 및 이의 용도
Kempaiah et al. Reduced Hsp70 and glutamine in pediatric severe malaria anemia: role of hemozoin in suppressing Hsp70 and NF-κB activation
Wang et al. Comparative suppression of NLRP3 inflammasome activation with LPS-induced inflammation by blueberry extracts (Vaccinium spp.)
Park et al. Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts
Kamil et al. Interleukin‐15 and Tumor Necrosis Factor‐α in Iraqi Patients with Alopecia Areata
TW201834652A (zh) 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
Maurer et al. Polymorphism eNOS Glu298Asp modulates the inflammatory response of human peripheral blood mononuclear cells
WO2008012692A2 (en) Assay for efficacy of histone deacetylase inhibitors
Wei et al. Role of the NOD1/NF-κB pathway on bovine neutrophil responses to crude lipopolysaccharide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140828

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20150810

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160915

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160915

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000